Company: AEMD
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001683168-25-008271
Chunk: 44

Company: AETHLON MEDICAL INC
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 8
Chunk 44
---
, and financial position as of and for the period ended September 30, 2025. Estimates were made relating to useful lives of fixed
assets, impairment of assets, share-based compensation expense and accruals for clinical trial and research and development expenses.
Actual results could differ materially from those estimates. The accompanying condensed consolidated balance sheet at March 31, 2025 has
been derived from the audited consolidated balance sheet at March 31, 2025, contained in the above referenced 10-K. The results of operations
for the three and six months ended September 30, 2025 are not necessarily indicative of the results to be expected for the full year or
any future interim periods.

     9 

Reclassifications

Certain prior year balances within the unaudited
condensed consolidated financial statements have been reclassified to conform to the current year presentation, including the impact of
the reverse stock splits.

LIQUIDITY AND GOING CONCERN

Management expects existing cash as of September
30, 2025 to not be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these condensed
consolidated financial statements. As a result, there is substantial doubt about the Company’s ability to continue as a going concern.

We are actively evaluating a range of strategic
and financing options to extend our cash runway and support our ongoing operations, including clinical development activities. These options
include potential equity offerings and other funding opportunities. However, there can be no assurance that any such financing will be
available on acceptable terms, or at all.

Our ability to continue as a going concern is
dependent upon securing additional capital and successfully executing our business plans. If we are unable to raise additional capital
when needed, we may be forced to significantly curtail or cease operations, including research and development programs and clinical trials.

The accompanying unaudited condensed consolidated
financial statements have been prepared assuming that we will continue as a going concern, which contemplates, among other things, the
realization of assets and satisfaction of liabilities in the ordinary course of business.

Restricted Cash

As of September 30, 2025, we maintained a restricted
cash balance of $98,448 in an interest-bearing money market deposit account with JPMorgan Chase, which supports our lease obligations.
This balance includes a $5,000 buffer above the required security amount. 

2. LOSS PER COMMON SHARE

Basic loss per share is computed by dividing net
loss by the weighted